Anika Therapeutics, Inc. (ANIK) Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Specialties
Anika Therapeutics, Inc. NASDAQ:ANIK Healthcare · Medical - Devices
Mkt Cap $280.37M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
Anika Therapeutics (NASDAQ: ANIK) will release third quarter 2026 financial results before market open on Friday, November 6, 2026.
A conference call to discuss the results is scheduled for 8:30 a.m. ET the same day, with a live webcast and presentation materials available via the company's investor relations site.
The release contains no financial figures or business updates and serves only as scheduling notice.
• 10d ago AI analysis › Press Release ⚠ 2
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
This article is a paid advertisement ('news commentary') profiling Conexeu Sciences, not a corporate disclosure from AbbVie.
The piece mentions AbbVie only as a historical benchmark for owning the neuromodulator (Botox) and filler (Juvederm) categories within the medical aesthetics market.
No new operational, financial, or strategic information regarding AbbVie is disclosed or implied.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
Anika Reports Second Quarter 2026 Financial Results
Anika Therapeutics reported Q2 2026 revenue of $32.6 million, up 16% year-over-year, driven by a record $13.9 million in commercial channel revenue.
Gross margin expanded to 65%, contributing to net income of $3.3 million and adjusted EBITDA of $7.1 million, the highest since 2020.
Based on the strong performance, the company raised its full-year 2026 guidance for revenue growth to 5%-10% and adjusted EBITDA margin to 13%-17%.
Management also revised 2027 revenue guidance downward, removing Hyalofast from the forecast due to ongoing regulatory timing uncertainty.
• 3mo ago AI analysis › Press Release
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics announced it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026.
Management will host a conference call at 8:30 a.m. ET on the same day to discuss the results and business highlights.
A live audio webcast and presentation materials will be accessible through the Investor Relations section of the company's website.
• 3mo ago AI analysis › Press Release
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics disclosed the grant of 3,360 restricted stock units to one newly hired non-executive employee.
The grant was made under the company’s 2021 Inducement Plan as a material inducement for employment, complying with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in three equal annual installments, contingent on continuous service through each vesting date.
• 4mo ago AI analysis › Press Release
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
TELA Bio announced a strategic board refreshment with four new appointments and preliminary Q1 2026 revenue of $19.0 million, topping guidance of $18.5 million.
ANIK is mentioned only in the biography of incoming TELA director Joseph Capper, who has served on ANIK's board since May 2024.
The release concerns TELA Bio's governance and financial performance; it contains no material news regarding Anika Therapeutics.
• 6mo ago AI analysis › Press Release ● Major ⚠ 2
Anika Reports First Quarter 2026 Financial Results
Anika reported Q1 2026 revenue of $29.6 million, up 13% year-over-year, with gross margin expanding 810 basis points to 64.2% due to improved operational execution.
The margin expansion drove adjusted EBITDA to $4.3 million, a significant increase from $0.1 million in the prior year, while the company also completed a $15 million share repurchase at an average price of $10.76.
Management maintained its full-year 2026 revenue guidance of $114 million to $122.5 million, though two directors, Dr. Glenn Larsen and Bill Jellison, will step down at the upcoming annual meeting.
• 6mo ago AI analysis › Press Release ● Major
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
globenewswire.com • 6mo ago 
